Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant: Programmatic Grants to tackle health and health equity - LOI

University of Calgary

$13,360.00

Alternatives and Supplements to Patents for Pharmaceutical Innovation: A Multidisciplinary Exploration of Alternatives

FY 2010-11

Summary
The question of how society should promote pharmaceutical innovation is both pertinent and timely: drugs are an integral component of health care. Both pharmaceutical and biological therapies also hold the promise to treat more effectively various debilitating health problems. In the last three decades, however, the productivity of pharmaceutical R&D has declined markedly. At the same time, there is concern that too large a share of R&D investment is focused on me-too drugs and incremental improvements to existing blockbusters, relative to the amount of investment in drugs for neglected diseases and the diseases of poverty. Several different mechanisms to support pharmaceutical R&D have been proposed. These include both 'push' programs - public subsidies directed towards the cost of R&D - and 'pull' programs - impact-based rewards such as the Health Impact Fund and royalty-based schemes for new drugs. These mechanisms hold the promise to significantly increase the productivity of pharmaceutical R&D. Moreover, to the extent that these mechanisms do not rely on high prices paid by patients, they would mitigate problems of drug access, both domestically and in low-income countries. Supplementing the international patent system with other mechanisms could therefore produce more therapeutically useful drugs at lower prices. The evidence for policy making in this area, however, is incomplete. We therefore propose to quantify systematically the social benefits and costs of both our current system of pharmaceutical patents and the various alternative mechanisms that are claimed to spur innovation more effectively. We will frame the problems from the perspective of wealthy and developing countries, using Vietnam as a key case study.
Program
Operating Grant: Programmatic Grants to tackle health and health equity - LOI
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
209047
Name
Hollis Aidan
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Programmatic Grant in Health & Health Equity (LOI)
Projecttitle
Alternatives and Supplements to Patents for Pharmaceutical Innovation: A Multidisciplinary Exploration of Alternatives
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$13,360
Cihrequipment2
$0
Programname2
Operating Grant: Programmatic Grants to tackle health and health equity - LOI
Keyworddelim
Access To Drugs; Neglected Diseases; Open-Source Science; Patents; Pharmaceutical Innovation; Royalties And Prizes
Abstract
The question of how society should promote pharmaceutical innovation is both pertinent and timely: drugs are an integral component of health care. Both pharmaceutical and biological therapies also hold the promise to treat more effectively various debilitating health problems. In the last three decades, however, the productivity of pharmaceutical R&D has declined markedly. At the same time, there is concern that too large a share of R&D investment is focused on me-too drugs and incremental improvements to existing blockbusters, relative to the amount of investment in drugs for neglected diseases and the diseases of poverty. Several different mechanisms to support pharmaceutical R&D have been proposed. These include both 'push' programs - public subsidies directed towards the cost of R&D - and 'pull' programs - impact-based rewards such as the Health Impact Fund and royalty-based schemes for new drugs. These mechanisms hold the promise to significantly increase the productivity of pharmaceutical R&D. Moreover, to the extent that these mechanisms do not rely on high prices paid by patients, they would mitigate problems of drug access, both domestically and in low-income countries. Supplementing the international patent system with other mechanisms could therefore produce more therapeutically useful drugs at lower prices. The evidence for policy making in this area, however, is incomplete. We therefore propose to quantify systematically the social benefits and costs of both our current system of pharmaceutical patents and the various alternative mechanisms that are claimed to spur innovation more effectively. We will frame the problems from the perspective of wealthy and developing countries, using Vietnam as a key case study.
Competitiondate
201007
Approvedterm2
0 yr 5 mths
Pinamesdelim
Hollis, Aidan; Grootendorst, Paul V
Approvedterm
0 an 5 mois
Cihrcontribution2
Ethics Office~ $10,000~ $0~Inst of Population &Publ Hlth~ $3,360~ $0~